SecBot SecBot

NVAX

NOVAVAX INC
Nasdaq· Biological Products, (No Diagnostic Substances)· Inc. DE· CIK 0001000694 Biotech & Drug Discovery
$8.06 −0.47 (−5.51%)
Nov 16 4:00 PM ET · prev $8.53
Market cap
$1.4B
Small cap
Consensus
Buy
67% Buy or better · 15 analysts
Median target
$16.00
+99% · range $7.00–25.00
1 year
+18.5%
from $6.80 · Nov 17
30 days
−25.5%
from $10.82
52-week range
$6.22–12.82
−37% from high · low Nov 20
Avg volume 20D
6.15M
shares / day
Short interest
46.33M
≈28.1% of shares · −2.1%
Days to cover
7.6
at average volume
Insider net
$0
no open-market trades · since Mar 2
New fund stakes
1
Q3 2026 13F · 0 exits
Filing reports
9
analyzed by SecBot
SecBot read BULLISH 5 reports · 90 days
Balance 1 bearish · 2 bullish · 2 neutral oldest → newest, height = score
Avg score ·High conf. 4/5

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells since Mar 2. Recent filings are awards, exercises and tax withholding.

  • InstitutionsMIXED

    Q3 2026: 22 added (1 new), 18 trimmed or exited. Largest new: Hrt Financial $27.9M.

  • AnalystsBULLISH

    10 of 15 rate it Buy or better. Median target $16.00 (+99%).

  • Short sellersSTEADY

    Short interest −2.1% to 46.33M shares. 7.6 days to cover, ≈28.1% of shares.

  • TrendDOWNTREND

    23% below its 50-day average.

  • SocialQUIET

    No Reddit mentions this week. Last mention Nov 3.

Who's buying

13F· Q3 2026
1
new positions
0
exits
$27.9M
in new stakes
FundMoveSharesValue
HRT FINANCIAL LPNEW2,576,691$27.9M
JUPITER ASSET MANAGEMENT LTDDOUBLED2,467,223$26.7M
Invesco Ltd.DOUBLED1,483,912$16.0M
UBS Group AGTRIM1,356,158$14.7M
FEDERATED HERMES, INC.ADD1,063,875$11.5M
Jump Financial, LLCDOUBLED905,872$9.8M
FMR LLCADD867,253$9.4M
BARCLAYS PLCDOUBLED771,881$8.3M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

15 analysts
Buy 67% rate it Buy or better
Strong Buy4Buy6Hold2Sell2Strong Sell1
12-month targets · 9 analysts

Price is inside the target range. Median implies +99%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Nov 6, 2026B. Riley Securities
REITERATE
REITERATEBuy
Oct 15, 2026Citigroup
MAINTAIN
MAINTAINSell
Jun 11, 2026BTIG
REITERATE
REITERATEBuy

Washington

Corporate Lobbying

34 lobbying filings and 1 bills this company lobbies on, with spend, stage and how each bill touches it, are for subscribers.

Subscribe for Full Access

Insider ledger

Form 4
$0
open-market buys or sells · since Mar 2
DateInsiderTypeValue
Jun 20, 2026
Alton Gregg H
Director
Jun 20, 2026
EXERCISE18,880 sh
Jun 20, 2026
MOTT DAVID M
Director
Jun 20, 2026
EXERCISE18,880 sh
Jun 20, 2026
MCGLYNN MARGARET G
Director
Jun 20, 2026
EXERCISE18,880 sh
Jun 20, 2026
DOUGLAS RICHARD
Director
Jun 20, 2026
EXERCISE18,880 sh
Jun 20, 2026
King Rachel K.
Director
Jun 20, 2026
EXERCISE18,880 sh
Jun 20, 2026
Rodgers Richard J
Director
Jun 20, 2026
EXERCISE18,880 sh
Jun 18, 2026
Newton Charles W.
Director
Jun 18, 2026
AWARD21,270 sh
Jun 18, 2026
Shiver John W.
Director
Jun 18, 2026
AWARD21,270 sh

Earnings setup

Estimates

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q-$0.35-$0.45–-$0.24-14.0%$35.8M
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Oct 30, 2026
46,329,834
shares short
-2.1%
vs prior settlement
7.6
days to cover
≈28.1%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 11, 2026 Other
Novavax to Participate in Jefferies London Healthcare Conference
GAITHERSBURG, Md., Nov. 11, 2026 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that c
Nov 10, 2026 SEC
State Street Corporation filed a Schedule 13G disclosing a passive 5.4% beneficial ownership stake in Novavax as of…
SC 13G · Impact 3/10
Nov 5, 2026 SEC
Novavax reported Q3 2026 total revenue of $68M, a 3% decline from $70M in Q3 2025, and a GAAP net loss of $31M…
8-K · Impact 6/10
Oct 29, 2026 SEC
Novavax announced that Sanofi dosed the fifth patient in its Phase 3 influenza-COVID-19 combination vaccine trial…
8-K · Impact 5/10
Sep 30, 2026 Inst.
HRT FINANCIAL LP · NEW
2,576,691 shares ($27.9M)
Sep 30, 2026 Inst.
JUPITER ASSET MANAGEMENT LTD · DOUBLED
2,467,223 shares ($26.7M)
Jun 20, 2026 Insider
Alton Gregg H acquired via exercise 18,880 shares
Director
Jun 20, 2026 Insider
MOTT DAVID M acquired via exercise 18,880 shares
Director
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Nov 11, 2026
Press release
Novavax to Participate in Jefferies London Healthcare Conference
GAITHERSBURG, Md., Nov. 11, 2026 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that company management will participate in the…
Nov 5, 2026
Earnings result
NVAX Q3 2026 Earnings: EPS $-0.19 (+44.6% vs est)
Sep 2, 2026
Press release
Novavax to Participate in September Investor Conferences
GAITHERSBURG, Md., Sept. 2, 2026 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that company management will participate in the…
Aug 6, 2026
Earnings date
NVAX Q2 2026 Earnings Scheduled, 2026-08-06
Aug 4, 2026
Earnings date
NVAX Q2 2026 Earnings Scheduled, 2026-08-04

SecBot reports

9 filings · 3 bullish · 1 bearish · 5 neutral
All NVAX filing & press-release reports (9)